Among these mutations, EGFR mutation has been found in approximately 35% of NSCLC patients in East Asia; the L858R located in the tyrosine kinase domain of EGFR is the most common point of mutation, accounting for about 41% of all EGFR mutations [7,22]. Here, EGFR is linked to non-small cell lung carcinoma.